1. 首頁 > 健康養生 > >

一文看遍！這些ASH最新抗癌進展值得關注( 五 )

健康知識養生常識


[10]JanssenPresentsNewDataforTalquetamab,aFirst-in-ClassGPRC5DxCD3BispecificAntibody,SuggestingDurableResponsesinPatientswithHeavilyPretreatedMultipleMyeloma.RetrievedDecember12,2022fromhttps://www.jnj.com/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma
[11]AbbViePresentsDataatthe64thAmericanSocietyofHematology(ASH)AnnualMeetingEvaluatingEpcoritamab(DuoBody?-CD3xCD20)AcrossB-CellLymphomas.RetrievedDecember12,2022fromhttps://news.abbvie.com/news/press-releases/abbvie-presents-data-at-64th-american-society-hematology-ash-annual-meeting-evaluating-epcoritamab-duobody-cd3xcd20-across-b-cell-lymphomas.htm
[12]JanssenPresentsFirstDatafromMajesTEC-2TrialofTECVAYLI?(teclistamab-cqyv)inCombinationwithDARZALEXFASPRO?(daratumumabandhyaluronidase-fihj)andLenalidomideinRelapsedorRefractoryMultipleMyeloma.RetrievedDecemberfromhttps://www.jnj.com/janssen-presents-first-data-from-majestec-2-trial-of-tecvayli-teclistamab-cqyv-in-combination-with-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-and-lenalidomide-in-relapsed-or-refractory-multiple-myeloma
[13]100%ClinicalBenefitRateAchievedinPhase1bTrialEvaluatingAPVO436inCombinationwithVenetoclaxandAzacitidineforVenetoclaxTreatmentNa?vePatientswithAcuteMyeloidLeukemia(AML).RetrievedDecember12,2022fromhttps://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/100-clinical-benefit-rate-achieved-phase-1b-trial-evaluating
[14]IGMBiosciencesPresentsDatafromTcellEngagerPortfolioforHematologicMalignanciesat2022AmericanSocietyofHematologyAnnualMeeting.RetrievedDecember12,2022fromhttps://investor.igmbio.com/news-releases/news-release-details/igm-biosciences-presents-data-t-cell-engager-portfolio
[15]ALXOncologyAnnouncesInitialDatafromASPEN-05StudyofEvorpaceptinCombinationwithAzacitidineandVenetoclax,DemonstratingTolerabilityandPreliminaryActivityinPatientswithAcuteMyeloidLeukemia.RetrievedDecember12,2022fromhttps://ir.alxoncology.com/news-releases/news-release-details/alx-oncology-announces-initial-data-aspen-05-study-evorpacept
[16]HARPOONTHERAPEUTICSPRESENTSUPDATEDINTERIMRESULTSATASH2022FORNOVELTCELLENGAGERHPN217INRELAPSED/REFRACTORYMULTIPLEMYELOMA.RetrievedDecember12,2022fromhttps://ir.harpoontx.com/news-releases/news-release-details/harpoon-therapeutics-presents-updated-interim-results-ash-2022
[17]BODYOFEVIDENCEGROWSFROMZUMA-7STUDYSUPPORTINGINITIALTREATMENTWITHKITE’SYESCARTA?CART-CELLTHERAPYFORPATIENTSWITHRELAPSEDORREFRACTORYLARGEB-CELLLYMPHOMA.RetrievedDecember12,2022fromhttps://www.kitepharma.com/news/press-releases/2022/12/body-of-evidence-grows-from-zuma-7-study-supporting-initial-treatment-with-kites-yescarta-car-t-cell-therapy-for-patients-with-relapsed-or-refractor
[18]THREE-YEARFOLLOW-UPANALYSISOFKITE’SYESCARTA?CART-CELLTHERAPY(ZUMA-5TRIAL)-52%OFPATIENTSWITHINDOLENTLYMPHOMASCONTINUEDTOHAVEONGOINGRESPONSESATAMEDIANFOLLOW-UPOF40.5MONTHS.RetrievedDecember12,2022fromhttps://www.kitepharma.com/news/press-releases/2022/12/threeyear-followup-analysis-of-kites-yescarta-car-tcell-therapy-zuma5-trial--52-of-patients-with-indolent-lymphomas-continued-to-have-ongoin
【一文看遍！這些ASH最新抗癌進展值得關注】[19]AdicetBioReportsPositiveDatafromOngoingADI-001Phase1TrialinPatientswithRelapsedorRefractoryAggressiveB-CellNon-Hodgkin’sLymphoma(NHL).RetrievedDecember12,2022fromhttps://investor.adicetbio.com/news-releases/news-release-details/adicet-bio-reports-positive-data-ongoing-adi-001-phase-1-trial